Hyperkalemia – Epidemiology – Mature Markets

Clarivate Epidemiology’s coverage of hyperkalemia comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France, Germany, Italy, Spain, the United Kingdom, and Japan). We report both the incidence and prevalence of hyperkalemia for each country, as well as annualized case counts projected to the national population.

Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets.

Clarivate Epidemiology’s hyperkalemia forecast will answer the following questions:

• Of all people with hyperkalemia, how many in each of the major mature pharmaceutical markets have been formally diagnosed?
• Of all people diagnosed with hyperkalemia, how many in each of the major mature pharmaceutical markets are drug-treated?
• How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of hyperkalemia over the forecast period?

All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.

Clarivate Epidemiology forecasts the following hyperkalemia patient populations:

• Total prevalent cases.
• Total prevalent cases by severity.
• Diagnosed subpopulation(s).
• Treatment subpopulation(s).
• Diagnosed hyperkalemia-related hospitalization events.
• Diagnosed acute hospitalization events.

Note: Coverage may vary by country.